Parkinson's Disease/Movement Disorders News

Physical wellness and social functioning were adversely affected in adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia, according to research in the Journal of Patient-Reported Outcomes.

Physical wellness and social functioning were adversely affected in adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia, according to research in the Journal of Patient-Reported Outcomes.

BOSTON — Treatment with an investigational combination of low-dose pramipexole and rasagiline led to less excessive daytime sleepiness and fewer adverse events compared with pramipexole alone in early Parkinson’s disease, research showed.

BOSTON — A survey of patients with Parkinson’s disease revealed knowledge gaps about the use of deep brain stimulation, according to a poster at the American Academy of Neurology annual meeting.

In this edition, trichloroethylene may be ‘invisible’ cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more.

Researchers have postulated that the environmental contaminant trichloroethylene may be contributing to the rise in Parkinson’s disease, according to a literature review in the Journal of Parkinson’s Disease.

Healio’s top stories on Parkinson’s disease in the first portion of 2023 include an FDA inquiry into a treatment pump, adjunctive therapy for carbidopa/levodopa and results from several clinical trials. Here’s what you may have missed:

Adding once-daily opicapone 50 mg to carbidopa/levodopa therapy helped achieve and maintain plasma concentrations of levodopa in patients with Parkinson’s disease, according to research in Clinical Neuropharmacology.

The FDA has issued a complete response letter to AbbVie regarding its new drug application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

CuraSen Therapeutics Inc. announced positive data from its randomized, double-blind crossover phase 2 study of CST-103/CST-107, which demonstrated improvements in cognition and mood in those with Parkinson’s disease.